The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT Annual Meeting is one of the largest gatherings of toxicologists from around the world. We are excited to join the thousands of attendees and hundreds of exhibitors in exchanging knowledge, publishing research findings, and learning Read more about vivoVerse at the Society of Toxicology Annual Meeting in Nashville[…]
vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. The new headquarters comprises over 2400 square-foot of laboratory, office, and meeting space and is situated in the Balcones Office Park, just north of downtown and UT Austin. Here, we lead you on a quick Read more about vivoVerse moves into new HQ[…]
Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have resumed operations in our lab and in our manufacturing facility as of August 1st. This means we can now be contacted for purchasing our vivoCube system, accessory kits, and for obtaining more vivoChips for your Read more about Newormics resumes operations[…]
Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, TX. August 5, 2020 – vivoVerse (formerly operating as Newormics), a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering Read more about vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office[…]
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies. vivoVerse’s core focus is to facilitate the use of C. elegans as Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]
Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global community effort. As we navigate this uncharted landscape together with you, our first concern is to express best wishes for the safety and security of yourselves and your families. We want to be in touch Read more about COVID-19 UPDATE[…]
Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with using conventional anesthetics and time-consuming mounting methods. To help researchers solve these problems, Newormics is launching two new devices in our vivoChip®-2x range: vivoChip®-2x L1-L2, Read more about Newormics launches new vivoChips for early stage worms[…]
The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search for phenotypic impacts in drug screening”. This article reviews cutting-edge research in drug discovery using novel microscopy and image analysis technologies to screen potential drug Read more about DDNews features Newormics in their latest issue in a special report on drug screening[…]
Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also have a special laboratory demo day, kindly hosted by Dr. Michalis Barkoulas at Imperial College London on September 17th. The demo will allow attendees to Read more about Newormics at the 2019 UK C. elegans meeting[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids”. Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
Dr. Lento is a serial COO/VPO executive for life science startups with broad skills in pharmaceuticals, medical devices, and diagnostics. With a unique background of equal parts government, public and private sector service, Dr. Lento holds a PhD in Biochemistry and additional credentials in Drug Evaluation, Pharmaceutical Sciences, and Corporate Governance, as well as an MBA in Healthcare Administration.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities at vivoVerse. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.
Jacob Moore completed his master’s and PhD in mechanical engineering at the University of Texas at Austin before joining the vivoVerse team. From his experimental research in the gas turbine industry, he developed a hands-on expertise in thermal/fluids systems that he is applying to chip and system designs. In addition, he is using his automated laboratory measurement experience to mature automation designs using vivoVerse technology.
Nicholas Chavez graduated with a Bachelors in Computational Biomedical Engineering from The University of Texas at Austin. After spending time as a software engineer in the tech industry, he has returned to the biotech field in the capacity of a bioimaging software engineer for vivoVerse. Here, he aids the company with the automation of data acquisition and processing as well as the development of embedded systems and full stack processes.